---
input_text: Administration of branched-chain amino acids alters the balance between
  pro-inflammatory and anti-inflammatory cytokines. Acute leucine intoxication and
  neurologic deterioration can develop rapidly at any age as a result of net protein
  degradation precipitated by infection or psychological stress in patients with maple
  syrup urine disease (MSUD). Here, we investigated the effects of acute and chronic
  Hyper-BCAA (H-BCAA) administration on pro- and anti-inflammatory cytokines in the
  brains of rats. For acute administration, Wistar rats (10 and 30 days) received
  three injections of BCAA pool (15.8 muL/g at 1-h intervals) or saline, subcutaneously.
  For chronic administration, Wistar rats (7 days) received of BCAA pool or saline
  twice a day for 21 days, subcutaneously. Our results showed that acute administration
  of H-BCAA increased IL-1beta (~ 78%; p <= 0.009) and TNF-alpha (~ 155%; p <= 0.026)
  levels in the cerebral cortex but not in the hippocampus of infant rats. Moreover,
  IL-6 levels were increased in the hippocampus (~ 135%; p <= 0.009) and cerebral
  cortex (~ 417%; p <= 0.008), whereas IL-10 levels were decreased only in the hippocampus
  (~ 42%; p <= 0.009). However, repeated administration of H-BCAA decreased IL-1beta
  (~ 59%; p <= 0.047), IL-6 (~ 70%; p <= 0.009) and IFN-gamma (~ 70%; p <= 0.008)
  levels in the cerebral cortex, whereas the IL-6 (~ 67%; p <= 0.009), IL-10 (~ 58%;
  p <= 0.01) and IFN-gamma (~ 67%; p <= 0.009) levels were decreased in the hippocampus.
  These findings suggest that a better understanding of the inflammatory response
  in MSUD patients may be useful to develop therapeutic strategies to modulate the
  hyperinflammatory/hypoinflammatory axis.
raw_completion_output: |-
  primary_disease: Maple Syrup Urine Disease (MSUD)
  medical_actions: Administration of branched-chain amino acids; Acute H-BCAA administration; Chronic H-BCAA administration
  symptoms: Acute leucine intoxication; Neurologic deterioration; Increased IL-1beta; Increased TNF-alpha; Increased IL-6; Decreased IL-10
  chemicals: Branched-chain amino acids; IL-1beta; TNF-alpha; IL-6; IL-10; IFN-gamma
  action_annotation_relationships: Administration of branched-chain amino acids TREATS Acute leucine intoxication IN Maple Syrup Urine Disease (MSUD); Chronic H-BCAA administration TREATS Increased IL-1beta IN Maple Syrup Urine Disease (MSUD); Chronic H-BCAA administration TREATS Increased TNF-alpha IN Maple Syrup Urine Disease (MSUD); Chronic H-BCAA administration TREATS Increased IL-6 IN Maple Syrup Urine Disease (MSUD); Chronic H-BCAA administration TREATS Decreased IL-10 IN Maple Syrup Urine Disease (MSUD); Acute H-BCAA administration (with IL-1beta) TREATS Neurologic deterioration IN Maple Syrup Urine Disease (MSUD); Acute H-BCAA administration (with TNF-alpha) TREATS Neurologic deterioration IN Maple Syrup Urine Disease (MSUD); Acute H-BCAA administration (with IL-6) TREATS Neurologic deterioration IN Maple Syrup Urine Disease (MSUD); Acute H-BCAA administration (with IL-10) PREVENTS Neurologic deterioration IN Maple Syrup Urine Disease (MSUD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Acute H-BCAA administration (with IL-10) PREVENTS Neurologic deterioration IN Maple Syrup Urine Disease (MSUD)

  ===

extracted_object:
  primary_disease: MONDO:0009563
  medical_actions:
    - Administration of branched-chain amino acids
    - Acute H-BCAA administration
    - Chronic H-BCAA administration
  symptoms:
    - Acute leucine intoxication
    - HP:0002344
    - Increased IL-1beta
    - Increased TNF-alpha
    - Increased IL-6
    - Decreased IL-10
  chemicals:
    - CHEBI:22918
    - IL-1beta
    - TNF-alpha
    - IL-6
    - IL-10
    - IFN-gamma
  action_annotation_relationships:
    - subject: Administration of branched-chain amino acids
      predicate: TREATS
      object: Acute leucine intoxication
      qualifier: MONDO:0009563
      subject_extension: CHEBI:22918
    - subject: Chronic H-BCAA administration
      predicate: TREATS
      object: Increased IL-1beta
      qualifier: MONDO:0009563
      subject_qualifier: Chronic
      subject_extension: H-BCAA
    - subject: Chronic H-BCAA administration
      predicate: TREATS
      object: Increased TNF-alpha
      qualifier: MONDO:0009563
      subject_qualifier: Chronic
      subject_extension: H-BCAA
    - subject: Chronic administration
      predicate: TREATS
      object: Increased IL-6
      qualifier: MONDO:0009563
      subject_extension: H-BCAA
      object_extension: IL-6
    - subject: Chronic H-BCAA administration
      predicate: TREATS
      object: Decreased IL-10
      qualifier: MONDO:0009563
      subject_qualifier: Chronic
      subject_extension: H-BCAA
    - subject: Acute H-BCAA administration
      predicate: TREATS
      object: HP:0002344
      qualifier: MONDO:0009563
      subject_qualifier: with IL-1beta
      subject_extension: H-BCAA
    - subject: Acute H-BCAA administration
      predicate: TREATS
      object: HP:0002344
      qualifier: MONDO:0009563
      subject_extension: H-BCAA
      object_extension: with TNF-alpha
    - subject: Acute administration
      predicate: TREATS
      object: HP:0002344
      qualifier: MONDO:0009563
      subject_qualifier: Acute
      subject_extension: H-BCAA
      object_extension: with IL-6
    - subject: Acute H-BCAA administration
      predicate: PREVENTS
      object: HP:0002344
      qualifier: MONDO:0009563
      subject_qualifier: with IL-10
      subject_extension: H-BCAA
named_entities:
  - id: MONDO:0009563
    label: Maple syrup urine disease (MSUD)
  - id: CHEBI:25017
    label: Leucine
  - id: CHEBI:22359
    label: alloisoleucine (allo-ile)
  - id: HP:0100626
    label: End stage liver diseases
  - id: MONDO:0100193
    label: End stage liver diseases
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: MAXO:0001175
    label: Liver transplantation (LT)
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT)
  - id: CHEBI:24898
    label: isoleucine
  - id: CHEBI:27266
    label: valine
  - id: MAXO:0000088
    label: diet
  - id: HP:0001263
    label: mental and motor retardation
  - id: HP:0002098
    label: respiratory distress
  - id: MONDO:0008143
    label: Organic Acidemias (OAs)
  - id: MONDO:0000688
    label: Organic Acidemias
  - id: MONDO:0021055
    label: Familial amyloidotic polyneuropathy (FAP)
  - id: HP:0003159
    label: hyperoxaluria
  - id: MONDO:0002474
    label: primary hyperoxaluria
  - id: MONDO:0008294
    label: acute intermittent porphyria
  - id: HP:0011034
    label: Amyloidosis
  - id: HP:0011968
    label: Poor feeding
  - id: HP:0001259
    label: Coma
  - id: HP:0001252
    label: Hypotonia
  - id: HP:0002013
    label: vomiting
  - id: HP:0000737
    label: irritability
  - id: HP:0003256
    label: Coagulopathy
  - id: HP:0001993
    label: Ketoacidosis
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0017052
    label: intermediate maple syrup urine disease (iMSUD)
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:17895
    label: Tyr
  - id: CHEBI:16828
    label: Trp
  - id: CHEBI:141437
    label: His
  - id: CHEBI:16044
    label: Met
  - id: CHEBI:16857
    label: Thr
  - id: CHEBI:30011
    label: Gln
  - id: CHEBI:17295
    label: Phe
  - id: CHEBI:28300
    label: glutamine
  - id: CHEBI:16449
    label: alanine
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:27568
    label: selenium
  - id: CHEBI:27432
    label: alpha-linolenic acid (18:3n-3)
  - id: CHEBI:36005
    label: docosahexaenoic acid (22:6n-3)
  - id: CHEBI:17865
    label: Alpha-ketoisocaproate (KIC)
  - id: HP:0003811
    label: Neonatal death
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002615
    label: hypotension
  - id: HP:0002901
    label: hypocalcemia
  - id: HP:0001942
    label: metabolic acidosis
  - id: CHEBI:145810
    label: Insulin
  - id: MONDO:0008867
    label: biliary atresia
  - id: CHEBI:48430
    label: Alpha-ketoisocaproic acid (KIC)
  - id: MAXO:0000600
    label: renal replacement therapy (RRT)
  - id: MAXO:0000601
    label: dialysis
  - id: CHEBI:15603
    label: amino-acid mixture without leucine (Leu), valine, isoleucine
  - id: MAXO:0001495
    label: parenteral administration
  - id: MAXO:0000943
    label: Dried blood spot (DBS) monitoring
  - id: CHEBI:22918
    label: Branched-chain amino acids (BCAA)
  - id: CHEBI:33349
    label: <Dried blood spot (DBS)>
  - id: MONDO:0009949
    label: PC deficiency
  - id: HP:0001977
    label: abnormal blood clotting
  - id: HP:0000717
    label: Autism
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001250
    label: Seizures
  - id: MONDO:0004739
    label: <Urea cycle defects (UCD), organic acidemias (OA), maple syrup urine disease
      (MSUD)>
  - id: HP:0001987
    label: elevated ammonia levels
  - id: CHEBI:29987
    label: Glutamate
  - id: CHEBI:21547
    label: N-acetylaspartate (NAA)
  - id: CHEBI:16919
    label: Creatine
  - id: HP:0006846
    label: acute encephalopathy
  - id: HP:0033667
    label: mental impairment (IQ <= 70)
  - id: HP:0001943
    label: Hypoglycemia
  - id: HP:0001257
    label: Spasticity
  - id: HP:0000988
    label: Rash
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001919
    label: Acute kidney injury
  - id: HP:0030005
    label: Capillary leak syndrome
  - id: CHEBI:176838
    label: Riboflavin (vitamin B2)
  - id: CHEBI:176841
    label: Biotin (vitamin B7)
  - id: HP:0002878
    label: respiratory failure
  - id: HP:0010911
    label: Hyperleucinemia
  - id: MAXO:0001001
    label: gene therapy
  - id: HP:0000938
    label: osteopenia
  - id: CHEBI:28938
    label: ammonia
  - id: CHEBI:30860
    label: methylmalonic acid
  - id: CHEBI:15702
    label: Tissue plasminogen activator (tPA)
  - id: HP:0001699
    label: sudden death
  - id: MAXO:0000932
    label: Electroencephalography
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002586
    label: peritonitis
  - id: HP:0003774
    label: chronic renal failure
  - id: MONDO:0008723
    label: Very-long chain acyl-CoA dehydrogenase deficiency (VLCAD)
  - id: CHEBI:17453
    label: methylmalonate
  - id: MONDO:0002012
    label: Methylmalonic Acidemia
  - id: MONDO:0008815
    label: Argininosuccinic Aciduria (ASA)
  - id: MAXO:0000602
    label: Hemodialysis (HD)
  - id: HP:0002344
    label: Neurologic deterioration
